Cited by 328COVID-19 Clinical Research StudiesCOVID-19 epidemiological studiesLong-Term Effects of COVID-19

Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature

Open access
Bajgain, Kalpana Thapa, Badal, Sujan, Bajgain, Bishnu B., Santana, Maria J.·2021·American Journal of Infection Control

Abstract

Introduction On February 11, 2020 WHO designated the name "COVID-19" for the disease caused by "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2), a novel virus that quickly turned into a global pandemic. Risks associated with acquiring the virus have been found to most significantly vary by age and presence of underlying comorbidity. In this rapid literature review we explore the prevalence of comorbidities and associated adverse outcomes among individuals with COVID-19 and summarize our findings based on information available as of May 15, 2020.Methods A comprehensive systematic search was performed on PubMed, Medline, Scopus, Embase, and Google Scholar to find articles published until May 15, 2020. All relevant articles providing information on PCR tested COVID-19 positive patient population with clinical characteristics and epidemiological information were selected for review and analysis.Results A total of 27 articles consisting of 22,753 patient cases from major epicenters worldwide were included in the study. Major comorbidities seen in overall population were CVD (8.9%), HTN (27.4%), Diabetes (17.4%), COPD (7.5%), Cancer (3.5%), CKD (2.6%), and other (15.5%). Major comorbidity specific to countries included in the study were China (HTN 39.5%), South Korea (CVD 25.6%), Italy (HTN 35.9%), USA (HTN 38.9%), Mexico, (Other 42.3%), UK (HTN 27.8%), Iran (Diabetes 35.0%). Within fatal cases, an estimated 84.1% had presence of one or more comorbidity. Subgroup analysis of fatality association with having comorbidity had an estimated OR 0.83, CI [0.60-0.99], p<0.05.Conclusions Based on our findings, hypertension followed by diabetes and cardiovascular diseases were the most common comorbidity seen in COVID-19 positive patients across major epicenters world-wide. Although having one or more comorbidity is linked to increased disease severity, no clear association was found between having these risk factors and increased risk of fatality.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajic.2020.06.213

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In data from Wuhan, age was the main risk factor for COVID-19 progression to acute respiratory distress syndrome and end-organ failure.

    “data from Wuhan, China showed that age was the primary risk factor associated with COVID-19 progression to acute respiratory distress syndrome (ARDS) and end-organ failure7”

    From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 74 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [73]Yang J Zheng Y Gou X Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Int J Infect Dis 94 2020 91 95 32173574 PMC7194638

Cited by

Sorted by citations

Authors
Bajgain, K. T., Badal, S., Bajgain, B. B., & Santana, M. J.
Affiliations
  • University of Minnesota (US)
  • University of Calgary (CA)
Corresponding author
Bajgain, Bishnu B.
Venue
American Journal of Infection Control
Publisher
Elsevier BV
Published
2021-02
Volume
49
Issue
2
Pages
238-246
ISSN
0196-6553 (ISSN-L)
OpenAlex
W3042070402
Cited by
328
References
74
Citations by year
2026: 8 · 2025: 17 · 2024: 23 · 2023: 57 · 2022: 105 · 2021: 102 · 2020: 16
FWCI
3.31
Type
journal article
Language
en
Open access
Locations
  • American Journal of Infection Control (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Libraries and Cultural Resources (University of Calgary) (submittedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
Keywords
COVID-19 pandemic, SARS-CoV-2, comorbidities, hypertension, diabetes mellitus, cardiovascular disease, chronic obstructive pulmonary disease, chronic kidney disease, cancer, COVID-19 mortality, disease severity, risk factors
MeSH terms
COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hypertension, Male, Middle Aged, Neoplasms, Global Health, Comorbidity, Prevalence, Pulmonary Disease, Chronic Obstructive, Renal Insufficiency, Chronic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review